Boehringer Ingelheim’s investigational compound nerandomilast, which targets the PDE4B enzyme involved in fibrosis and ...

Increased funding and new public health policies for sickle cell research are needed to ease the burden on low-income nations ...

The German big pharma will submit a new drug application to the US FDA after success at phase 3 for nerandomilast.

The positive phase 3 results showed improved lung function with nerandomilast vs placebo at 52 weeks in idiopathic pulmonary ...

Ioannis Sapountzis, head of global therapeutic areas at Boehringer, said that FIBRONEER-IPF is the largest trial in IPF ...

This blog describes a typical ILD patient journey from the initial diagnosis through its long-term management to end-of-life ...

On September 17, 2024, the lord blessed Randall “Randy” Scott Hall a much-deserved poetic exit, after an acute exacerbation ...

John Edward Trube, born August 25, 1932, in Brooklyn, New York, passed away on September 19, 2024, in Peachtree City, Georgia ...

COVID-19 evolves like other common viruses and we’re grateful for updated vaccines to help prevent severe illness, ...

Delma Bryant Armstrong, age 83, of Murfreesboro, went home to be with the Lord on Tuesday, September 17, 2024 due to ...

2022 — Idiopathic pulmonary fibrosis (IPF) is an aging-associated disease caused by progressive scarring of the lungs, leading to respiratory failure and death. Therapies to treat IPF are ...